Predictions
Canadian Solar Inc.
Start price
Target price
Perf. (%)
€36.90
18.04.23
18.04.23
€30.00
18.04.24
18.04.24
-33.09%
09.09.23
09.09.23
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Fortuna Silver Mines Inc.
Start price
Target price
Perf. (%)
€3.60
16.04.23
16.04.23
-
16.04.24
16.04.24
-16.11%
30.05.23
30.05.23
Could be very worthwhile Investment >20% year
EBIT growth > 30% per year expected
Rising EBIT margin expected
Revenue growth > 30% per year expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.80
03.04.23
03.04.23
-
03.04.27
03.04.27
-12.14%
11.03.24
11.03.24
Could be worthwhile Investment >10% per year
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.78
03.04.23
03.04.23
-
03.04.24
03.04.24
0.20%
15.04.23
15.04.23
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€10.25
31.03.23
31.03.23
-
31.03.24
31.03.24
-4.55%
01.04.23
01.04.23
Aurora Cannabis Inc.
Start price
Target price
Perf. (%)
€0.63
29.03.23
29.03.23
€2.00
29.03.24
29.03.24
-42.33%
30.03.24
30.03.24
Absolute Software Corp.
Start price
Target price
Perf. (%)
€6.95
25.03.23
25.03.23
-
25.03.24
25.03.24
49.64%
31.05.23
31.05.23
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€8.87
24.03.23
24.03.23
-
24.03.24
24.03.24
12.58%
18.05.23
18.05.23
Could be very worthwhile Investment >20% year
InMed Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€1.30
20.03.23
20.03.23
-
20.03.24
20.03.24
6.18%
23.03.23
23.03.23
Could be worthwhile Investment >10% per year
Capable Management
Good culture
Little innovation
Canadian Solar Inc.
Start price
Target price
Perf. (%)
€36.73
11.03.23
11.03.23
€30.00
11.03.24
11.03.24
0.48%
18.04.23
18.04.23
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Promis Neurosciences Inc.
Start price
Target price
Perf. (%)
€4.22
11.03.23
11.03.23
€4.60
11.03.24
11.03.24
18.48%
19.05.23
19.05.23
ROE lower than 10% per year
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected